questionText: To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of NICE’s rejection of trastuzumab deruxtecan for use in secondary breast cancer treatment on patient outcomes.
answerText: Decisions on whether new medicines should be routinely funded by the National Health Service in England are made on the basis of recommendations from the National Institute for Health and Care Excellence (NICE) following an evaluation of a treatment’s cos...
heading: Trastuzumab Deruxtecan